{"id":740293,"date":"2023-03-15T08:52:51","date_gmt":"2023-03-15T12:52:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/"},"modified":"2023-03-15T08:52:51","modified_gmt":"2023-03-15T12:52:51","slug":"mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/","title":{"rendered":"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\u2013 Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors<\/p>\n<p>NEW YORK, March  15, 2023  (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to present updated clinical data and development plans in solid tumors at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19<sup>th<\/sup>, 2023.<\/p>\n<p>\n        <strong>Presentation Details<\/strong>\n      <\/p>\n<p>Title: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors<\/p>\n<p>Abstract Number: CT275<\/p>\n<p>Session Title: Phase I Clinical Trials 2<\/p>\n<p>Session Date and Time: Tuesday April 18, 2023, 1:30 PM &#8211; 5:00 PM ET<\/p>\n<p>Presenting Author: Dr. Benedito Carneiro<\/p>\n<p>\n        <strong>About MiNK Therapeutics<\/strong>\n      <\/p>\n<p>MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UItsWmFT73IYY4E_9svGwWHa_ShglJjWIPg0wDl3fM_Xbuvbq7B3f-b6yPZuvNS8MCbQs8Dih0VBBME4p4MiivVspsEVRzFmiRkaKu3cO_C5MJOvW_Qtl5InsLID5oKx\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/minktherapeutics.com\/<\/a>. Follow us on Twitter @MiNK_iNKT.<\/p>\n<p>\n        <strong>Contact<br \/><\/strong>Alexa Buffa<br \/>781-674-4428<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GkkbuKMGe1NhP-JRz6EFPoycPR5_Z9q1IzFLJEzaov9bDkNkao9ns5CtP2wD7MneEFXy_GOP5LODg_r8n_L0MwlpxzQ5RQUiHBNfq59_coqn958QFTEjO3CZ32C3YpHlrEPLzp8LNbBRjbvTdYjEAw==\" rel=\"nofollow noopener\" target=\"_blank\">communications@minktherapeutics.com<\/a><\/p>\n<p>Investor relations:<br \/>Zack Armen<br \/>917-362-1370<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Ca4TIlyLpP1UDFyY4tVA_2YXdySWa7i0ULWHZJkefqY607F6lnY7j9K60kxPkXrZpLkEVbKhRoHTMLXbP3rzed8_ZKd3pk3U0csc_hTyVA2wd8xcii-breNnXHJwt8h\" rel=\"nofollow noopener\" target=\"_blank\">investor@minktherapeutics.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDhkODVjZTEtZmE5ZS00ZGE3LThmYjItNTk0MjRkZDcxZGQzLTEyMzQ3NjQ=\/tiny\/MiNK-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to present updated clinical data and development plans in solid tumors at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19th, 2023. Presentation Details Title: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors Abstract Number: CT275 Session Title: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740293","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to present updated clinical data and development plans in solid tumors at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19th, 2023. Presentation Details Title: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors Abstract Number: CT275 Session Title: &hellip; Continue reading &quot;MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T12:52:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting\",\"datePublished\":\"2023-03-15T12:52:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/\"},\"wordCount\":250,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/\",\"name\":\"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=\",\"datePublished\":\"2023-03-15T12:52:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting - Market Newsdesk","og_description":"\u2013 Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to present updated clinical data and development plans in solid tumors at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19th, 2023. Presentation Details Title: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors Abstract Number: CT275 Session Title: &hellip; Continue reading \"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-15T12:52:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting","datePublished":"2023-03-15T12:52:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/"},"wordCount":250,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/","name":"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=","datePublished":"2023-03-15T12:52:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODQ2OCM1NDYyMzI2IzIyMjMyMTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-present-updated-clinical-data-of-allo-inkt-cell-therapy-in-solid-tumors-at-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740293"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740293\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}